Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to $141.7 million.

  • Silence Therapeutics' Shares Outstanding (Weighted Average) rose 1.06% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year increase of 1.06%. This contributed to the annual value of $141.6 million for FY2024, which is 22.10% up from last year.
  • Silence Therapeutics' Shares Outstanding (Weighted Average) amounted to $141.7 million in Q3 2025, which was up 0.01% from $141.7 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $141.7 million in Q3 2025 and a low of $83.3 million during Q1 2021.
  • Over the past 3 years, Silence Therapeutics' median Shares Outstanding (Weighted Average) value was $131.9 million (recorded in 2024), while the average stood at $127.1 million.
  • Data for Silence Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 29.24% (in 2024) over the last 5 years.
  • Over the past 5 years, Silence Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $89.8 million in 2021, then rose by 19.94% to $107.7 million in 2022, then grew by 7.74% to $116.0 million in 2023, then grew by 22.10% to $141.6 million in 2024, then grew by 1.06% to $141.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $141.7 million for Q3 2025, versus $141.7 million for Q2 2025 and $141.7 million for Q1 2025.